216 related articles for article (PubMed ID: 37501126)
1. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
[TBL] [Abstract][Full Text] [Related]
2. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
[TBL] [Abstract][Full Text] [Related]
3. Challenges in orphan drug development and regulatory policy in China.
Cheng A; Xie Z
Orphanet J Rare Dis; 2017 Jan; 12(1):13. PubMed ID: 28100254
[TBL] [Abstract][Full Text] [Related]
4. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
5. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Gammie T; Lu CY; Babar ZU
PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
[TBL] [Abstract][Full Text] [Related]
6. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
7. Current status and trend of clinical development of orphan drugs in China.
Xiang Z; Jiang W; Yan B; Jiang J; Zheng H
Orphanet J Rare Dis; 2022 Jul; 17(1):294. PubMed ID: 35897012
[TBL] [Abstract][Full Text] [Related]
8. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
Guan X; Zhang J; Man C; Ni B; Shi L
J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
[TBL] [Abstract][Full Text] [Related]
9. Research and development of mAb drugs in China: a look from policy perspectives.
Jiang R; Sun Y; Ung C; Dong X; Kong X; Hu Y; Shao R
Hum Vaccin Immunother; 2019; 15(11):2695-2705. PubMed ID: 31116629
[No Abstract] [Full Text] [Related]
10. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
11. The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.
Choudhury MC; Saberwal G
Orphanet J Rare Dis; 2019 Nov; 14(1):241. PubMed ID: 31684990
[TBL] [Abstract][Full Text] [Related]
12. Traits, trends and hits of orphan drug designations in cystic fibrosis.
Costa E; Girotti S; van den Ham HA; Cipolli M; van der Ent CK; Taylor-Cousar JL; Leufkens HGM
J Cyst Fibros; 2023 Sep; 22(5):949-957. PubMed ID: 37507282
[TBL] [Abstract][Full Text] [Related]
13. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
14. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
15. [Current Status and Issues in Drug Development for Rare Cancers].
Kashitani Y; Takayama H; Hamada N; Go S; Tagami M; Sugihara T
Gan To Kagaku Ryoho; 2023 Nov; 50(11):1150-1154. PubMed ID: 38056864
[TBL] [Abstract][Full Text] [Related]
16. Orphan drug development in China: progress and challenges.
Zhang S; Chen L; Zhang Z; Zhao Y
Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
[No Abstract] [Full Text] [Related]
17. Orphan drugs policies: a suitable case for treatment.
Drummond M; Towse A
Eur J Health Econ; 2014 May; 15(4):335-40. PubMed ID: 24435513
[TBL] [Abstract][Full Text] [Related]
18. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
Le TT
Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
[TBL] [Abstract][Full Text] [Related]
19. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.
Harada K; Toriyabe K; Ono S
J Clin Pharmacol; 2020 Jan; 60(1):117-124. PubMed ID: 31364772
[TBL] [Abstract][Full Text] [Related]
20. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
